Neuronetics, Inc. (STIM)
| Market Cap | 223.26M +3.3% |
| Revenue (ttm) | 155.10M +39.6% |
| Net Income | -30.43M |
| EPS | -0.44 |
| Shares Out | 76.20M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,362,454 |
| Open | 2.850 |
| Previous Close | 2.880 |
| Day's Range | 2.820 - 3.010 |
| 52-Week Range | 0.800 - 3.710 |
| Beta | 1.17 |
| Analysts | Strong Buy |
| Price Target | 6.00 (+104.78%) |
| Earnings Date | Aug 11, 2026 |
About STIM
Neuronetics, Inc. engages in providing in office treatments for patients with neurohealth disorders in the United States and internationally. The company provides NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company... [Read more]
Financial Performance
In 2025, Neuronetics's revenue was $149.16 million, an increase of 99.17% compared to the previous year's $74.89 million. Losses were -$39.00 million, -10.78% less than in 2024.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for STIM stock is "Strong Buy." The 12-month stock price target is $6.0, which is an increase of 104.78% from the latest price.
News
Neuronetics management to meet virtually with BTIG
Virtual Meeting to be held on September 15 hosted by BTIG.
NeuroStar Advances Practice Innovation with First-Ever TMS Integration with an EHR/EMR System
MALVERN, Pa., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a leader in interventional mental health and provider of NeuroStar® TMS technology and direct patient care through th...
Neuronetics Earnings Call Transcript: Q2 2026
Q2 2026 revenue grew 9.1% year-over-year to $41.6 million, led by Greenbrook clinics and improved operational efficiency. Gross margin rose to 61.1%, net loss narrowed, and adjusted EBITDA turned positive. Guidance was tightened, with continued focus on profitability and growth in interventional psychiatry.
Neuronetics Slides: Q2 2026
Neuronetics has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 11, 2026.
Neuronetics Earnings release: Q2 2026
Neuronetics released its Q2 2026 earnings on August 11, 2026, summarizing the period's financial results.
Neuronetics Quarterly report: Q2 2026
Neuronetics has published its Q2 2026 quarterly earnings report on August 11, 2026.
Neuronetics reports Q2 EPS (5c), consensus (12c)
Reports Q2 revenue $41.57M, consensus $40.17M. “This was a quarter of real operational progress, and meaningful steps toward our goal of sustained profitability and positive net cash flow from operati...
Neuronetics and Jorey Chernett Announce Shared Vision
MALVERN, Pa., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (“Neuronetics” or the “Company”) and Jorey Chernett, the Company's second largest shareholder and Managing Member of Po...
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
MALVERN, Pa., July 31, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a leader in interventional mental health that combines its NeuroStar® TMS technology with direct patient care through ...
Greenbrook Opens National Center of Excellence for Advanced Interventional Psychiatry in Rockville, Maryland
New location expands access to advanced mental health treatments while serving as Greenbrook's flagship innovation center and blueprint for future care delivery New location expands access to advanced...
Neuronetics to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call
MALVERN, Pa., July 28, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a leader in interventional mental health that combines its NeuroStar® TMS technology with direct patient care through ...
Neuronetics appoints Nir Naor as CFO, CLO Andrew Macan to step down
Neuronetics (STIM) announced that Nir Naor will be appointed CFO effective July 23. Most recently, he served as CFO of Axogen (AXGN). Separately, Andrew Macan, executive VP, chief legal officer…
Neuronetics Appoints Nir Naor Chief Financial Officer; Announces Additional Management Changes
MALVERN, Pa., July 20, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a leader in interventional mental health that combines its NeuroStar® TMS technology with direct patient care through ...
Neuronetics initiated with a Buy at BTIG
BTIG initiated coverage of Neuronetics (STIM) with a Buy rating and $5 price target The late 2024 acquisition of Greenbrook TMS transformed the company from a pure-play medical device manufacturer…
Neuronetics to Participate in a Panel Discussion at B. Riley Securities' Mind, Muscle & Vision Summit on July 16, 2026
MALVERN, Pa., July 06, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a leader in interventional mental health that combines its NeuroStar® TMS technology with direct patient care through ...
Neuronetics Appoints Robert Greene as Senior Vice President Sales
MALVERN, Pa., June 02, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life...
Neuronetics Highlights Continued Advancements in TMS Research at CTMSS 2026
MALVERN, Pa., June 02, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life...
Neuronetics Transcript: AGM 2026
All director nominees were re-elected, auditor appointment and executive compensation were approved, and the 2026 Equity Incentive Plan passed. No shareholder questions were raised, and final voting results will be filed with the SEC.
Neuronetics and ANT Neuro Announce Strategic Collaboration to Integrate Neuronavigation with NeuroStar TMS Treatment
MALVERN, Pa., May 14, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life ...
Neuronetics reports Q1 EPS (16c), consensus (17c)
Reports Q1 revenue $34.45M, consensus $34.18M. “I’m encouraged by our first quarter performance, which reflects the team’s continued execution on revenue growth, operational efficiency, and cash manag...
Neuronetics backs FY26 revenue view $160M-$166M, consensus $162.47M
Sees Q2 revenue up mid-single digits.
Neuronetics Earnings Call Transcript: Q1 2026
Q1 2026 revenue grew 8% year-over-year to $34.5 million, with improved net loss and adjusted EBITDA. Clinic revenue rose 15% on strong SPRAVATO growth, while NeuroStar system sales increased but treatment revenue declined. Guidance and cash outlook remain stable.
Neuronetics Earnings release: Q1 2026
Neuronetics released its Q1 2026 earnings on May 5, 2026, summarizing the period's financial results.
Neuronetics Slides: Q1 2026
Neuronetics has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 5, 2026.
Neuronetics Quarterly report: Q1 2026
Neuronetics has published its Q1 2026 quarterly earnings report on May 5, 2026.